# Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

> **NCT00209417** · PHASE4 · TERMINATED · sponsor: **GE Healthcare** · enrollment: 656 (actual)

## Conditions studied

- Renal Insufficiency
- Diabetes Mellitus

## Interventions

- **DRUG:** Iodixanol 320-Arm 1
- **DRUG:** Iopamidol 300-Arm 2

## Key facts

- **NCT ID:** NCT00209417
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-07
- **Target enrollment:** 656 (ACTUAL)
- **Why stopped:** Supported by preliminary interim analysis. Not based on any safety signals in study or any quality issues that could affect efficacy of the product.
- **Last updated:** 2014-10-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209417, "Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00209417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*